Neo-adjuvant chemotherapy ± immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: A pilot study

Biotherapy ◽  
1994 ◽  
Vol 8 (2) ◽  
pp. 91-98 ◽  
Author(s):  
Giovanni Mantovani ◽  
Alessandro Bianchi ◽  
Luigi Curreli ◽  
Massimo Ghiani ◽  
Maria Cristina Santona ◽  
...  
1987 ◽  
Vol 5 (3) ◽  
pp. 456-458 ◽  
Author(s):  
J T Johnson ◽  
E N Myers ◽  
V L Schramm ◽  
D G Mayernik ◽  
T A Nolan ◽  
...  

A prospective clinical trial was developed to evaluate efficacy, toxicity, and patient compliance to adjuvant chemotherapy following surgery and postoperative radiation therapy in patients with squamous-cell carcinoma of the head and neck with extracapsular spread of tumor in cervical metastases. Following postoperative radiation therapy, 18 courses of methotrexate (MTX) and 5-fluorouracil (5-FU) were administered over 6 months. Fifty patients were registered. A total of 771 doses were administered. Dose reduction was required 72 times. Therapy was stopped in one patient (2%) because of toxicity. Three patients (6%) refused to complete the adjuvant therapy. Adjusted 2-year no evidence of disease (NED) survival is 66%. This study demonstrates that patients with advanced squamous-cell carcinoma of the head and neck can undertake an aggressive program of adjuvant MTX/5-FU with acceptable compliance and toxicities. Preliminary data generated in this nonrandomized study support the call for a prospective randomized multiinstitutional trial of this program.


Head & Neck ◽  
2007 ◽  
Vol 29 (3) ◽  
pp. 267-271 ◽  
Author(s):  
Ozlem E. Tulunay ◽  
Ileana I. Enamorado ◽  
Omer Kucuk ◽  
Lance K. Heilbrun ◽  
Jose E. Otero ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document